Evaluation of the Clinical Benefit of Cancer Drugs Submitted for Reimbursement Recommendation Decisions in Canada

FDA Approval and Regulation of Pharmaceuticals, 1983-2018

(2020) Jonathan J. Darrow et al.   JAMA-JOURNAL OF THE AMERICAN MEDICAL ASSOCIATION

FDA Acceptance of Surrogate End Points for Cancer Drug Approval: 1992-2019

(2020) Emerson Y. Chen et al.   JAMA Internal Medicine

Limitations in Clinical Trials Leading to Anticancer Drug Approvals by the US Food and Drug Administration

(2020) Talal Hilal et al.   JAMA Internal Medicine

Association between commercial funding of Canadian patient groups and their views about funding of medicines: An observational study

(2019) Joel Lexchin   PLoS One

Financial conflicts of interest of clinicians making submissions to the pan-Canadian Oncology Drug Review: a descriptive study

(2019) Joel Lexchin   BMJ Open

Design characteristics, risk of bias, and reporting of randomised controlled trials supporting approvals of cancer drugs by European Medicines Agency, 2014-16: cross sectional analysis

(2019) Huseyin Naci et al.   BMJ-British Medical Journal

The Relative Importance of Clinical, Economic, Patient Values and Feasibility Criteria in Cancer Drug Reimbursement in Canada: A Revealed Preferences Analysis of Recommendations of the Pan-Canadian Oncology Drug Review 2011–2017

(2018) Chris Skedgel et al.   PHARMACOECONOMICS

Examining Trends in Cost and Clinical Benefit of Novel Anticancer Drugs Over Time

(2018) Ronak Saluja et al.   Journal of Oncology Practice

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration Based on Single-Arm Trials

(2018) Ariadna Tibau et al.   JAMA Oncology

A systematic review of trial-level meta-analyses measuring the strength of association between surrogate end-points and overall survival in oncology

(2018) Alyson Haslam et al.   EUROPEAN JOURNAL OF CANCER

New Cancer Drug Approvals From the Perspective of a Universal Healthcare System: Analyses of the Pan-Canadian Oncology Drug Review Recommendations

(2018) Saroj Niraula et al.   Journal of the National Comprehensive Cancer Network

Evaluating Progression-Free Survival as a Surrogate Outcome for Health-Related Quality of Life in Oncology

(2018) Bruno Kovic et al.   JAMA Internal Medicine

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

(2017) Ariadna Tibau et al.   JNCI-Journal of the National Cancer Institute

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

(2017) Courtney Davis et al.   BMJ-British Medical Journal

Availability of evidence of benefits on overall survival and quality of life of cancer drugs approved by European Medicines Agency: retrospective cohort study of drug approvals 2009-13

(2017) Courtney Davis et al.   BMJ-British Medical Journal

Magnitude of Clinical Benefit of Cancer Drugs Approved by the US Food and Drug Administration

(2017) Ariadna Tibau et al.   JNCI-Journal of the National Cancer Institute

An Appraisal of Clinically Meaningful Outcomes Guidelines for Oncology Clinical Trials

(2016) Hemanth Kumar et al.   JAMA Oncology

Cancer Drugs Approved on the Basis of a Surrogate End Point and Subsequent Overall Survival

(2015) Chul Kim et al.   JAMA Internal Medicine

Five Years of Cancer Drug Approvals

(2015) Sham Mailankody et al.   JAMA Oncology

American Society of Clinical Oncology Perspective: Raising the Bar for Clinical Trials by Defining Clinically Meaningful Outcomes

(2014) Lee M. Ellis et al.   JOURNAL OF CLINICAL ONCOLOGY

Unintended Consequences of Expensive Cancer Therapeutics—The Pursuit of Marginal Indications and a Me-Too Mentality That Stifles Innovation and Creativity

(2014) Tito Fojo et al.   JAMA Otolaryngology-Head & Neck Surgery

Progression-Free Survival: Meaningful or Simply Measurable?

(2012) Christopher M. Booth et al.   JOURNAL OF CLINICAL ONCOLOGY